210 related articles for article (PubMed ID: 22302327)
1. Medication use and spending trends among children with ADHD in Florida's Medicaid program, 1996-2005.
Fullerton CA; Epstein AM; Frank RG; Normand SL; Fu CX; McGuire TG
Psychiatr Serv; 2012 Feb; 63(2):115-21. PubMed ID: 22302327
[TBL] [Abstract][Full Text] [Related]
2. Medication patterns for attention-deficit/hyperactivity disorder and comorbid psychiatric conditions in a low-income population.
Radigan M; Lannon P; Roohan P; Gesten F
J Child Adolesc Psychopharmacol; 2005 Feb; 15(1):44-56. PubMed ID: 15741785
[TBL] [Abstract][Full Text] [Related]
3. Early diagnoses and psychotherapeutic medication treatment experiences of a cohort of children under 6 years old who received antipsychotic treatment in Florida's Medicaid program.
Constantine RJ; Tandon R; McPherson M; Andel R
J Child Adolesc Psychopharmacol; 2011 Feb; 21(1):79-84. PubMed ID: 21288122
[TBL] [Abstract][Full Text] [Related]
4. Differential Risk of Increasing Psychotropic Polypharmacy Use in Children Diagnosed With ADHD as Preschoolers.
Winterstein AG; Soria-Saucedo R; Gerhard T; Correll CU; Olfson M
J Clin Psychiatry; 2017 Jul; 78(7):e744-e781. PubMed ID: 28686819
[TBL] [Abstract][Full Text] [Related]
5. National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007.
Comer JS; Olfson M; Mojtabai R
J Am Acad Child Adolesc Psychiatry; 2010 Oct; 49(10):1001-10. PubMed ID: 20855045
[TBL] [Abstract][Full Text] [Related]
6. Period prevalence of concomitant psychotropic medication usage among children and adolescents with attention-deficit/hyperactivity disorder during 2009.
Betts KA; Sikirica V; Hodgkins P; Zhou Z; Xie J; DeLeon A; Erder MH; Wu EQ
J Child Adolesc Psychopharmacol; 2014 Jun; 24(5):260-8. PubMed ID: 24839998
[TBL] [Abstract][Full Text] [Related]
7. Psychotropic medication use in a population of children who have attention-deficit/hyperactivity disorder.
Guevara J; Lozano P; Wickizer T; Mell L; Gephart H
Pediatrics; 2002 May; 109(5):733-9. PubMed ID: 11986429
[TBL] [Abstract][Full Text] [Related]
8. Determinants of initial pharmacological treatment for youths with attention-deficit/hyperactivity disorder.
Chen CY; Gerhard T; Winterstein AG
J Child Adolesc Psychopharmacol; 2009 Apr; 19(2):187-95. PubMed ID: 19364296
[TBL] [Abstract][Full Text] [Related]
9. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.
Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Muriel AC; Frank RG
Arch Gen Psychiatry; 2005 Apr; 62(4):435-41. PubMed ID: 15809411
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis of attention-deficit/hyperactivity disorder and use of psychotropic medication in very young children.
Rappley MD; Mullan PB; Alvarez FJ; Eneli IU; Wang J; Gardiner JC
Arch Pediatr Adolesc Med; 1999 Oct; 153(10):1039-45. PubMed ID: 10520611
[TBL] [Abstract][Full Text] [Related]
11. Psychotropic Polypharmacy Among Children and Youth Receiving Medicaid, 2012-2015.
Lohr WD; Creel L; Feygin Y; Stevenson M; Smith MJ; Myers J; Woods C; Liu G; Davis DW
J Manag Care Spec Pharm; 2018 Aug; 24(8):736-744. PubMed ID: 30058983
[TBL] [Abstract][Full Text] [Related]
12. Attention-Deficit/Hyperactivity Disorder and Psychotropic Polypharmacy Prescribing Trends.
Girand HL; Litkowiec S; Sohn M
Pediatrics; 2020 Jul; 146(1):. PubMed ID: 32487590
[TBL] [Abstract][Full Text] [Related]
13. Antipsychotic Treatment Among Youths With Attention-Deficit/Hyperactivity Disorder.
Sultan RS; Wang S; Crystal S; Olfson M
JAMA Netw Open; 2019 Jul; 2(7):e197850. PubMed ID: 31348506
[TBL] [Abstract][Full Text] [Related]
14. Prescribing for young people with attention deficit hyperactivity disorder in UK primary care: analysis of data from the Clinical Practice Research Datalink.
Newlove-Delgado T; Hamilton W; Ford TJ; Stein K; Ukoumunne OC
Atten Defic Hyperact Disord; 2019 Sep; 11(3):255-262. PubMed ID: 30730035
[TBL] [Abstract][Full Text] [Related]
15. ADHD medication use, adherence, persistence and cost among Texas Medicaid children.
Barner JC; Khoza S; Oladapo A
Curr Med Res Opin; 2011; 27 Suppl 2():13-22. PubMed ID: 21973228
[TBL] [Abstract][Full Text] [Related]
16. Correlating Psychotropic Use to Major Depressive Disorder and ADHD Research Diagnoses: Trends in a Prospective Pediatric Cohort From Ages 3 to 21.
Liang MU; Charatcharungkiat N; Tillman R; Patel HM; Vogel AC; Luby JL
J Clin Psychiatry; 2022 Oct; 83(6):. PubMed ID: 36321921
[No Abstract] [Full Text] [Related]
17. An analysis of the slowdown in growth of spending for psychiatric drugs, 1986-2008.
Mark TL; Kassed C; Levit K; Vandivort-Warren R
Psychiatr Serv; 2012 Jan; 63(1):13-8. PubMed ID: 22227754
[TBL] [Abstract][Full Text] [Related]
18. Psychiatric Comorbidities and Psychotropic Medication Use in Autism: A Matched Cohort Study with ADHD and General Population Comparator Groups in the United Kingdom.
Houghton R; Liu C; Bolognani F
Autism Res; 2018 Dec; 11(12):1690-1700. PubMed ID: 30380202
[TBL] [Abstract][Full Text] [Related]
19. Psychiatric comorbidities and use of psychotropic medications in people with autism spectrum disorder in the United States.
Houghton R; Ong RC; Bolognani F
Autism Res; 2017 Dec; 10(12):2037-2047. PubMed ID: 28963809
[TBL] [Abstract][Full Text] [Related]
20. Use and cost of psychotropic drugs among recipients with autism in a state Medicaid fee-for-service programme.
Khanna R; Jariwala K; West-Strum D
J Intellect Disabil Res; 2013 Feb; 57(2):161-71. PubMed ID: 22471524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
